PARD3 and breast carcinoma: Likewise, Par3 has been described as a metastasis inhibitor in pancreatic and breast cancer; however, it has also been shown that in those two cases that Par3 presents an alternative splicing, which could change its interaction capacities with target factors including Rac1 (Ke et al., 2018).